This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.
500 mg/m2, intravenous (IV), every 21 days x 6 cycles
100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
Bahía Blanca, Argentina
Buenos Aires, Argentina
Mar del Plata, Argentina
Rosario, Argentina
Tucumain, Argentina